EGM
LVTX

Engineers Gate Manager’s LAVA Therapeutics LVTX Stock Holding History

Engineers Gate Manager’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,985
Closed -$30.4K – 2400
2024
Q4 		$30.4K Buy
31,985
+20,095
+169% +$31.6K ﹤0.01% 2135
2024
Q3 		$19.7K Buy
+11,890
New +$21.8K ﹤0.01% 2029

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Engineers Gate Manager's LVTX Position: Q1 2025 in Review

Engineers Gate Manager sold out of LAVA Therapeutics (LVTX) in Q1 2025, closing a stake of 31,985 shares — an estimated $30.4K sold.

Engineers Gate Manager first reported a position in LVTX in Q3 2024 and held it in 2 quarters. The position peaked at $30.4K in Q4 2024. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2025.

  • Engineers Gate Manager reported no remaining LAVA Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 31,985 LAVA Therapeutics shares in Q1 2025, an estimated $30.4K.
  • Engineers Gate Manager first reported a position in LAVA Therapeutics in Q3 2024 and held it in 2 quarters.
  • Engineers Gate Manager's LAVA Therapeutics position peaked at $30.4K in Q4 2024.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.